Historical record - last NADAC effective date: 3/20/2019
Product Information
TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $3.6356 per EA under NDC 68462032901. Its NADAC has been published 167 times since May 18, 2016.
FDA first approved this application on May 5, 2010.
Strength
4; 240 mg/1; mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462032901
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
3/20/2019
Active Ingredients
TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA079135FDA Approved
5/5/2010
On Market Since
2/25/2015
Pharmacological Classes
Price Statistics
The NADAC for TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET has been published 167 times since May 18, 2016, and over the history we have for it it has declined 5.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.6356 per EA |
|---|---|
| All-time high | $4.0543 (Sep 13, 2017) |
| All-time low | $3.6356 (Aug 22, 2018) |
| Median price | $3.8248 |
| Average price | $3.8205 |
| Largest weekly change | -8.9% (Aug 22, 2018) |
| Weeks tracked | 167 |
| Tracking since | May 18, 2016 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-5.4%
Last surveyed Aug 14, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Trandolapril and Verapamil Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Trandolapril and Verapamil Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $3.6356 per EA (NDC 68462032901), effective Aug 14, 2019.
How has the price of TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET has declined 5.4%. It has been tracked across 167 weekly CMS publications since May 18, 2016.
What are the highest and lowest recorded NADAC prices for TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET?
Since May 18, 2016, the NADAC for TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET has ranged from a low of $3.6356 (Aug 22, 2018) to a high of $4.0543 (Sep 13, 2017), with a median of $3.8248 per EA.
Are there cheaper alternatives to TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET?
TRANDOLAPRIL-VERAPAMIL ER 4-240 MG TABLET (NDC 68462032901) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.